Glutamate transporters: A key piece in the glutamate puzzle of major depressive disorder

Journal of Psychiatric Research

Volumn 47, Issue 9, 2013, Pages 1150-1156

  Medina, Adriana ^a   Burke, Sharon ^a   Thompson, Robert C ^a   Bunney, William ^b   Myers, Richard M ^c   Schatzberg, Alan ^d   Akil, Huda ^a   Watson, Stanley J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Glutamate; Glutamate transporters; Hippocampus; In situ hybridization; Laser capture microdissection; Major depression disorder; Microarray

Indexed keywords

GLUTAMATE TRANSPORTER; VESICULAR GLUTAMATE TRANSPORTER;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; MAJOR DEPRESSION; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL;

EID: 84880136368     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.04.007     Document Type: Article

References (63)

1. Altamura C., Maes M., Dai J., Meltzer H.Y. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995, 5(Suppl):71-75.
2. Amara S.G., Fontana A.C. Excitatory amino acid transporters: keeping up with glutamate. Neurochemistry International 2002, 41(5):313-318.
3. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007 Sep, 32(9):1888-1902. Epub 2007 Feb 14.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000 Feb 15, 47(4):351-354.
5. Bernard R., Kerman I.A., Meng F., Evans S.J., Amrein I., Jones E.G., et al. Gene expression profiling of neurochemically defined regions of the human brain by in situ hybridization-guided laser capture microdissection. J Neurosci Methods 2009 Mar 30, 178(1):46-54. Epub 2008 Nov 25. 10.1016/j.jneumeth.2008.11.012.
6. Bernard R., Kerman I.A., Thompson R.C., Jones E.G., Bunney W.E., Barchas J.D., et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. Mol Psychiatry 2011 Jun, 16(6):634-646.
7. Bjørnsen L.P., Eid T., Holmseth S., Danbolt N.C., Spencer D.D., de Lanerolle N.C. Changes in glial glutamate transporters in human epileptogenic hippocampus: inadequate explanation for high extracellular glutamate during seizures. Neurobiol Dis 2007 Feb, 25(2):319-330. Epub 2006 Nov 16.
8. Bunney B.G., Bunney W.E. Rapid-acting antidepressant strategies: mechanisms of action. The International Journal of Neuropsychopharmacology 2012, 15(5):695-713.
9. Bunney B.G., Bunney W.E., Carlsson A. Schizophrenia and glutamate. Psychopharmacology: the fourth generation of progress 1995, 1205-1214. Raven Press, New York. F.E.K. Bloom, D.J. Kupfer (Eds.).
10. Camacho A., Massieu L. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Archives of Medical Research 2006, 37(1):11-18.
11. Campiani G., Fattorusso C., De Angelis M., Catalanotti B., Butini S., Fattorusso R., et al. Neuronal high-affinity sodium-dependent glutamate transporters (EAATs): targets for the development of novel therapeutics against neurodegenerative diseases. Curr Pharm Des 2003, 9(8):599-625.
12. Carlsson M., Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome?. Schizophrenia Bulletin 1990, 16(3):425-432.
13. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry Suppl 1999, 37:2-6.
14. Choudary P.V., Molnar M., Evans S.J., Tomita H., Li J.Z., Vawter M.P., et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005 Oct 25, 102(43):15653-15658.
15. Clinton S.M., Bedrosian T.A., Abraham A.D., Watson S.J., Akil H. Neural and environmental factors impacting maternal behavior differences in high- versus low-novelty-seeking rats. Horm Behav 2010 Apr, 57(4-5):463-473.
16. Clinton S.M., Kerman I.A., Orr H.R., Bedrosian T.A., Abraham A.D., Simpson D.N., et al. Pattern of forebrain activation in high novelty-seeking rats following aggressive encounter. Brain Res. 2011 Nov 8, 1422:20-31.
17. Connolly K.R., Thase M.E. Emerging drugs for major depressive disorder. Expert Opinion on Emerging Drugs 2012, 17(1):105-126.
18. Cotman C.W., Monaghan D.T. Anatomical organization of excitatory amino acid receptors and their properties. Advances in Experimental Medicine and Biology 1986, 203:237-252.
19. Danbolt N.C. Glutamate uptake. Progress in Neurobiology 2001, 65(1):1-105.
20. Danbolt N.C., Storm-Mathisen J., Ottersen O.P. Sodium/potassium-coupled glutamate transporters, a "new" family of eukaryotic proteins: do they have "new" physiological roles and could they be new targets for pharmacological intervention?. Prog Brain Res. 1994, 100:53-60.
21. Danbolt N.C., Chaudhry F.A., Dehnes Y., Lehre K.P., Levy L.M., Ullensvang K., et al. Properties and localization of glutamate transporters. Prog Brain Res. 1998, 116:23-43.
22. Dehnes Y., Chaudhry F.A., Ullensvang K., Lehre K.P., Storm-Mathisen J., Danbolt N.C. The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J Neurosci 1998 May 15, 18(10):3606-3619.
23. Demarque M., Villeneuve N., Manent J.B., Becq H., Represa A., Ben-Ari Y., et al. Glutamate transporters prevent the generation of seizures in the developing rat neocortex. J Neurosci 2004 Mar 31, 24(13):3289-3294.
24. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010 Aug, 67(8):793-802.
25. Dingledine R., McBain C. Glutamate and aspartate. Basic neurochemistry: molecular, cellular and medical aspects 1999, Lippincott-Raven, Philadelphia. G.J. Siegel, B.W. Agranoff, R.W. Albers, S.K. Fisher, M.D. Uhler (Eds.).
26. Dong X.X., Wang Y., Qin Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009 Apr, 30(4):379-387.
27. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008 Sep, 213(1-2):93-118. Epub 2008 Aug 13. 10.1007/s00429-008-0189-x.
28. Featherstone R.E., Liang Y., Saunders J.A., Tatard-Leitman V.M., Ehrlichman R.S., Siegel S.J. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 2012 Sep, 47(3):338-346.
29. Feyissa A.M., Chandran A., Stockmeier C.A., Karolewicz B. Reduced levels of NR2A andNR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009 Feb 1, 33(1):70-75. 10.1016/j.pnpbp.2008.
30. Flagel S.B., Watson S.J., Robinson T.E., Akil H. Individual differences in the propensity to approach signals vs goals promote different adaptations in the dopamine system of rats. Psychopharmacology (Berl) 2007 Apr, 191(3):599-607.
31. Fremeau R.T., Voglmaier S., Seal R.P., Edwards R.H. VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci 2004 Feb, 27(2):98-103.
32. Gegelashvili G., Robinson M.B., Trotti D., Rauen T. Regulation of glutamate transporters in health and disease. Prog Brain Res. 2001, 132:267-286.
33. Greenamyre J.T., Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurology 1994, 44(11 Suppl. 8):S7-S13.
34. Harrison P.J., Law A.J., Eastwood S.L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann N Y Acad Sci 2003 Nov, 1003:94-101.
35. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007 Dec 1, 62(11):1310-1316.
36. Jones E.G., Hendry S.H., Liu X.B., Hodgins S., Potkin S.G., Tourtellotte W.W. A method forfixation of previously fresh-frozen human adult and fetal brains that preserves histological quality and immunoreactivity. J Neurosci Methods 1992 Sep, 44(2-3):133-144.
37. Kabbaj M., Devine D.P., Savage V.R., Akil H. Neurobiological correlates of individual differences in novelty-seeking behavior in the rat: differential expression of stress-related molecules. J Neurosci 2000 Sep 15, 20(18):6983-6988.
38. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000 Oct 1, 48(7):627-640.
39. Kim J.S., Schmid-Burgk W., Claus D., Kornhuber H.H. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232(4):299-304.
40. Krolewski D.M., Medina A., Kerman I.A., Bernard R., Burke S., Thompson R.C., et al. Expression patterns of corticotropin-releasing factor, arginine vasopressin, histidine decarboxylase, melanin-concentrating hormone, and orexin genes in the human hypothalamus. J Comp Neurol 2010 Nov 15, 518(22):4591-4611.
41. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12(13):2971-2974.
42. Liévens J.C., Salin P., Nieoullon A., Kerkerian-Le Goff L. Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem 2001 Nov, 79(4):893-902.
43. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009 Oct, 15(5):525-539.
44. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpé S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998 Apr, 97(4):302-308.
45. Maragakis N.J., Rothstein J.D. Glutamate transporters in neurologic disease. Archives of Neurology 2001, 58(3):365-370.
46. Maragakis N.J., Rothstein J.D. Glutamate transporters: animal models to neurologic disease. Neurobiology of Disease 2004, 15(3):461-473.
47. Mathern G.W., Mendoza D., Lozada A., Pretorius J.K., Dehnes Y., Danbolt N.C., et al. Hippocampal GABA and glutamate transporter immunoreactivity in patients with temporal lobe epilepsy. Neurology 1999 Feb, 52(3):453-472.
48. Mathews D.C., Henter I.D., Zarate C.A. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012 Jul 9, 72(10):1313-1333.
49. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Progress in Neurobiology 1998, 54(4):369-415.
50. Murray C.J., Lopez A.D. Evidence-based health policy-lessons from the global burden of disease study. Science 1996, 274(5288):740-743.
51. Murrough J.W., Perez A.M., Mathew S.J., Charney D.S. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry 2011 Mar, 72(3):414-415.
52. Noga J.T., Hyde T.M., Herman M.M., Spurney C.F., Bigelow L.B., Weinberger D.R., et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997 Nov, 27(3):168-176.
53. Nowak G., Ordway G.A., Paul I.A. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995 Mar 27, 675(1-2):157-164.
54. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009 Sep 1, 66(5):522-526.
55. Simmons R.K., Howard J.L., Simpson D.N., Akil H., Clinton S.M. DNA methylation in the developing hippocampus and amygdala of anxiety-prone versus risk-taking rats. Dev Neurosci 2012, 34(1):58-67.
56. Sinner B., Graf B.M. Ketamine. Handbook of Experimental Pharmacology 2008, 182:313-333.
57. Storm-Mathisen J. Glutamate in hippocampal pathways. Advances in Biochemical Psychopharmacology 1981, 27:43-55.
58. Thomas R.J. Excitatory amino acids in health and disease. Journal of the American Geriatrics Society 1995, 43(11):1279-1289.
59. Tomita H., Vawter M.P., Walsh D.M., Evans S.J., Choudary P.V., Li J., Overman K.M., et al. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 2004 Feb 15, 55(4):346-352.
60. Torp R., Danbolt N.C., Babaie E., Bjørås M., Seeberg E., Storm-Mathisen J., et al. Differential expression of two glial glutamate transporters in the rat brain: an in situ hybridization study. Eur J Neurosci 1994 Jun 1, 6(6):936-942.
61. Van der Hel W.S., Verlinde S.A., Meijer D.H., de Wit M., Rensen M.G., van Gassen K.L., et al. Hippocampal distribution of vesicular glutamate transporter 1 in patients with temporal lobe epilepsy. Epilepsia 2009 Jul, 50(7):1717-1728.
62. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71(11):939-946.
63. Zarate C.A., Mathews D., Ibrahim L., Chaves J.F., Marquardt C., Ukoh I., Jolkovsky L., et al. A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression. Biol Psychiatry 2012, Nov 30.